After stock investors drove down its share price last week, Valeant Pharmaceuticals International Inc. finds its fate in the hands of its debtholders, the Wall Street Journal reported today. Valeant said today that it would begin talks with its loan investors, as it faces a potential default on its debt if it can’t file its 2015 annual report, or 10-K, by late April. A deal is considered highly likely, investors and analysts said, because most debt investors still believe Valeant is capable of paying the interest on its roughly $30 billion debt load, even if the Canadian company doesn’t realize shareholders’ dreams of a rebound. Shares have lost about 90 percent since their August high, partly out of fear that equity investors would be left with nothing if there were a default.
